Crispr Therapeutics AG (CRSP) Insider Trading
- $28,147,755.86
- $317,726,279.25
- March 11, 2025
- Samarth Kulkarni
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
March 11, 2025 | CEO | 9,973 | $42.42 | Sell | $423,054.66 | |
March 11, 2025 | COO | 1,198 | $42.42 | Sell | $50,819.16 | |
March 11, 2025 | General Counsel | 2,850 | $42.42 | Sell | $120,897.00 | |
Feb. 26, 2025 | Director | 7,000 | $44.85 | Buy | $313,950.00 | |
Feb. 19, 2025 | CEO | 18,360 | $55.20 | Sell | $1,013,472.00 | |
Dec. 2, 2024 | CEO | 15,000 | $55.10 | Sell | $826,500.00 | |
Nov. 11, 2024 | CEO | 30,000 | $55.62 | Sell | $1,668,600.00 | |
Oct. 14, 2024 | CEO | 4,293 | $46.28 | Sell | $198,680.04 | |
Oct. 14, 2024 | General Counsel | 1,089 | $46.28 | Sell | $50,398.92 | |
June 21, 2024 | COO | 3,366 | $56.09 | Sell | $188,798.94 | |
April 15, 2024 | CEO | 19,582 | $59.91 | Sell | $1,173,157.62 | |
March 15, 2024 | CFO | 3,524 | $72.69 | Sell | $256,159.56 | |
March 15, 2024 | CEO | 20,000 | $72.48 | Sell | $1,449,600.00 | |
March 11, 2024 | General Counsel | 2,801 | $78.26 | Sell | $219,206.26 | |
March 11, 2024 | CEO | 9,802 | $78.26 | Sell | $767,104.52 | |
Feb. 20, 2024 | CEO | 6,370 | $79.67 | Sell | $507,497.90 | |
Feb. 20, 2024 | General Counsel | 1,913 | $79.67 | Sell | $152,408.71 | |
Feb. 15, 2024 | CEO | 20,000 | $80.36 | Sell | $1,607,200.00 | |
Jan. 29, 2024 | CEO | 50,000 | $60.51 | Sell | $3,025,500.00 | |
Jan. 16, 2024 | CEO | 20,000 | $62.50 | Sell | $1,250,000.00 | |
May 30, 2023 | CEO | 25,000 | $64.88 | Sell | $1,622,000.00 | |
April 25, 2023 | CEO | 25,000 | $50.67 | Sell | $1,266,750.00 | |
March 29, 2023 | CEO | 25,000 | $44.46 | Sell | $1,111,500.00 | |
Feb. 27, 2023 | CEO | 25,000 | $48.25 | Sell | $1,206,250.00 | |
Jan. 27, 2023 | CEO | 25,000 | $51.47 | Sell | $1,286,750.00 | |
Dec. 28, 2022 | CEO | 25,000 | $40.93 | Sell | $1,023,250.00 | |
Nov. 28, 2022 | CEO | 25,000 | $54.03 | Sell | $1,350,750.00 | |
Oct. 26, 2022 | CEO | 25,000 | $54.81 | Sell | $1,370,250.00 | |
Sept. 28, 2022 | CEO | 25,000 | $64.61 | Sell | $1,615,250.00 | |
Aug. 29, 2022 | CEO | 25,000 | $66.84 | Sell | $1,671,000.00 | |
July 27, 2022 | CEO | 25,000 | $75.91 | Sell | $1,897,750.00 | |
June 29, 2022 | CEO | 25,000 | $61.59 | Sell | $1,539,750.00 | |
Aug. 6, 2021 | CFO | 25,000 | $138.52 | Sell | $3,463,000.00 | |
Aug. 4, 2021 | CEO | 1,500 | $125.02 | Sell | $187,530.00 | |
July 19, 2021 | Director | 10,000 | $126.43 | Sell | $1,264,300.00 | |
June 30, 2021 | President | 25,000 | $165.00 | Sell | $4,125,000.00 | |
June 28, 2021 | Director | 20,375 | $152.48 | Sell | $3,106,780.00 | |
June 21, 2021 | President | 25,000 | $128.62 | Sell | $3,215,500.00 | |
June 15, 2021 | CEO | 30,000 | $126.43 | Sell | $3,792,900.00 | |
June 11, 2021 | Director | 10,000 | $126.61 | Sell | $1,266,100.00 | |
March 22, 2021 | Director | 30,374 | $132.37 | Sell | $4,020,606.38 | |
Jan. 19, 2021 | General Counsel | 27,500 | $204.94 | Sell | $5,635,850.00 | |
Jan. 15, 2021 | COO | 25,000 | $215.20 | Sell | $5,380,000.00 | |
Jan. 15, 2021 | CEO | 20,000 | $213.67 | Sell | $4,273,400.00 | |
Dec. 21, 2020 | VP | 23,551 | $149.23 | Sell | $3,514,515.73 | |
Dec. 16, 2020 | Director | 7,648 | $148.95 | Sell | $1,139,169.60 | |
Dec. 10, 2020 | CEO | 20,000 | $142.29 | Sell | $2,845,800.00 | |
Dec. 10, 2020 | Director | 33,000 | $143.35 | Sell | $4,730,550.00 | |
Dec. 7, 2020 | Director | 171,004 | $154.53 | Sell | $26,425,248.12 | |
Nov. 30, 2020 | President | 100,000 | $125.00 | Sell | $12,500,000.00 |
Insiders are both buying and selling Crispr Therapeutics AG stock.
The insider traders at Crispr Therapeutics AG are: Samarth Kulkarni, Rodger Novak, Kurt Von Emster, Bradley J Phd Bolzon, Corp /De/ Celgene, Tyler Dylan-Hyde, Pablo J Cagnoni, Lawrence Otto Klein, James R Kasinger, Thomas Woiwode, Vertex Pharmaceuticals (Europe, Julianne Bruno, Michael John Tomsicek, John Greene, Simeon George, James R. Kasinger, Tony W Ho, Tony W. Ho, Bradley J. Phd Bolzon, Versant Venture Capital V, L.P, Aktiengesellschaft Bayer, and Raju Prasad
The most active insider trader at Crispr Therapeutics AG is Samarth Kulkarni with 36 trades.
Kurt Von Emster has sold the most Crispr Therapeutics AG stock with a total value of $68,130,025.01.
Aktiengesellschaft Bayer has bought the most Crispr Therapeutics AG stock with a total value of $23,999,976.00.
The most recent insider trade for Crispr Therapeutics AG was on March 11, 2025.
The single biggest insider buy for Crispr Therapeutics AG was from Aktiengesellschaft Bayer with a total value of $11,999,988.00 on Jan. 5, 2018.
The single biggest insider sell for Crispr Therapeutics AG was from Kurt Von Emster with a total value of $35,353,500.00 on May 14, 2018.